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ABSTRACT 
In patients over the age of 65 especially, bone fractures represent a significant disease burden. Non-invasive 
drug therapies are not available for bone fractures which represents a problem for this population. Vasoactive 
intestinal peptide (VIP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), two neuromodulator 
peptides in the glucagon superfamily, have demonstrated positive regulation of osteoblast proliferation and 
activity. Using acidic oligopeptides, we have developed ligands that target to and accumulate at fracture sites. 
These targeting ligands can be synthesized in sequence with bone anabolic peptides to minimize off target 
effects and increase potency at the fracture site to create safer and more efficacious therapeutic molecules. The 
conjugation of PACAP and VIP to acidic oligopeptide targeting ligands results in compounds that demonstrate 
significant improvements in regeneration of bone at fracture site in vivo in terms of strength and mineralization of 
fracture callus. 
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